ECSP044961A - Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides - Google Patents

Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides

Info

Publication number
ECSP044961A
ECSP044961A EC2004004961A ECSP044961A ECSP044961A EC SP044961 A ECSP044961 A EC SP044961A EC 2004004961 A EC2004004961 A EC 2004004961A EC SP044961 A ECSP044961 A EC SP044961A EC SP044961 A ECSP044961 A EC SP044961A
Authority
EC
Ecuador
Prior art keywords
chlorosaliciloil
aminocaprilico
acid
supply agent
hormone fragments
Prior art date
Application number
EC2004004961A
Other languages
English (en)
Inventor
Moise Azria
Simon David Bateman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP044961A publication Critical patent/ECSP044961A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones farmacéuticas para el suministro oral efectivo de una hormona paratiroides, PTH, así como métodos para la administración de las composiciones. Además, también se proporcionan métodos para estimular la formación de nuevos huesos y/o prevenir osteoporosis.
EC2004004961A 2001-08-17 2004-01-29 Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides ECSP044961A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17

Publications (1)

Publication Number Publication Date
ECSP044961A true ECSP044961A (es) 2004-03-23

Family

ID=23214149

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004004961A ECSP044961A (es) 2001-08-17 2004-01-29 Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides

Country Status (26)

Country Link
US (4) US20040242478A1 (es)
EP (1) EP1420827B8 (es)
JP (2) JP4959917B2 (es)
KR (1) KR20040030120A (es)
CN (1) CN1279981C (es)
AT (1) ATE443527T1 (es)
AU (1) AU2002333443C1 (es)
BR (1) BRPI0211932B1 (es)
CA (1) CA2453646C (es)
CO (1) CO5560586A2 (es)
CY (1) CY1109661T1 (es)
DE (1) DE60233803D1 (es)
DK (1) DK1420827T3 (es)
EC (1) ECSP044961A (es)
ES (1) ES2333587T3 (es)
HU (1) HUP0401441A3 (es)
IL (2) IL159714A0 (es)
MX (1) MXPA04001418A (es)
NO (1) NO328069B1 (es)
NZ (1) NZ531018A (es)
PL (1) PL210258B1 (es)
PT (1) PT1420827E (es)
RU (1) RU2322256C2 (es)
SI (1) SI1420827T1 (es)
WO (1) WO2003015822A1 (es)
ZA (1) ZA200400242B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5073153B2 (ja) * 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
KR20040030120A (ko) * 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
EP1496911B1 (en) * 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Use of a combination comprising a2a adenosine receptor agonists and anti-pathogenic agents for the treatment of inflammatory diseases
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
ES2398237T3 (es) 2003-07-23 2013-03-14 Novartis Ag Uso de calcitonina en osteoartritis
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US8110547B2 (en) * 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
JP2008543855A (ja) * 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ， インコーポレイテッド 変形性骨疾患を処置するための方法および組成物
CN105641686A (zh) 2005-09-19 2016-06-08 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
BRPI0716261A2 (pt) * 2006-08-31 2013-08-06 Novartis Ag composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
CN101621991A (zh) 2007-03-02 2010-01-06 诺瓦提斯公司 降钙素的口服施用
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
BR112012013725A2 (pt) 2009-12-07 2017-01-10 Univ Michigan Tech paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
US20180036382A1 (en) * 2015-02-09 2018-02-08 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
CN116850132A (zh) 2016-08-17 2023-10-10 安提拉生物有限公司 用于口服的活性剂的制剂
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
RU2112515C1 (ru) * 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза
EP0679088B1 (en) * 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
DK0915911T3 (da) * 1996-08-02 2004-03-08 Ca Nat Research Council Analoger til parathyreoideahormon til behandling af osteoporose
ATE383169T1 (de) * 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE69938064T2 (de) * 1998-11-25 2009-01-15 The General Hospital Corp., Boston Aminoterminal modifizierte parathyroidhormon (pth) analoge
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US6900344B2 (en) * 2000-03-21 2005-05-31 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
JP5073153B2 (ja) 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
KR20040030120A (ko) * 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
US20070065505A1 (en) * 2003-07-11 2007-03-22 Shoufeng Li Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Also Published As

Publication number Publication date
DE60233803D1 (de) 2009-11-05
US9272040B2 (en) 2016-03-01
ATE443527T1 (de) 2009-10-15
KR20040030120A (ko) 2004-04-08
US20060217313A1 (en) 2006-09-28
NO20040598L (no) 2004-02-10
HUP0401441A3 (en) 2012-09-28
JP2009242410A (ja) 2009-10-22
AU2002333443B2 (en) 2006-06-29
RU2004107899A (ru) 2005-05-10
US20040242478A1 (en) 2004-12-02
PT1420827E (pt) 2009-12-15
SI1420827T1 (sl) 2010-01-29
EP1420827B8 (en) 2009-12-23
CO5560586A2 (es) 2005-09-30
RU2322256C2 (ru) 2008-04-20
IL159714A (en) 2010-12-30
ZA200400242B (en) 2004-11-18
NO328069B1 (no) 2009-11-23
AU2002333443C1 (en) 2009-10-08
WO2003015822A1 (en) 2003-02-27
CN1279981C (zh) 2006-10-18
BR0211932A (pt) 2004-10-26
HUP0401441A2 (hu) 2004-12-28
MXPA04001418A (es) 2004-05-27
EP1420827B1 (en) 2009-09-23
US20090264367A1 (en) 2009-10-22
NZ531018A (en) 2006-03-31
JP2005501852A (ja) 2005-01-20
US20120088725A1 (en) 2012-04-12
PL210258B1 (pl) 2011-12-30
JP4959917B2 (ja) 2012-06-27
IL159714A0 (en) 2004-06-20
CA2453646C (en) 2008-09-30
CA2453646A1 (en) 2003-02-27
PL365388A1 (en) 2005-01-10
CY1109661T1 (el) 2014-08-13
CN1543357A (zh) 2004-11-03
DK1420827T3 (da) 2009-12-21
ES2333587T3 (es) 2010-02-24
EP1420827A1 (en) 2004-05-26
BRPI0211932B1 (pt) 2016-12-06

Similar Documents

Publication Publication Date Title
ECSP044961A (es) Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides
SE0100568D0 (sv) Compounds
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
MXPA03006841A (es) 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico.
WO2002067967A3 (en) Method of treating rhinitis or sinusitis
UY27886A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco.
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
SE0100566D0 (sv) Compounds
GB2446341A (en) Method and system for transdermal drug delivery
PE20000644A1 (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
SI1638582T1 (sl) Uporaba hialuronske kisline za pripravo sestav za zdravljenje ponavljajoäśih se aft v ustni votlini
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
GT200400134A (es) Sistemas emulsionantes que contienen derivados de azetidina
SE0101692D0 (sv) Compounds
SE0202365D0 (sv) New formulation and use thereof
AR013492A1 (es) Medicamento veterinario que contiene la coriogonadotrofina equina nativa o modificada para inducir la ovulacion en la yegua y estimular la produccion detestosterona en el semental.
WO2007023281A3 (en) Biologically active compounds
ECSP045056A (es) Composiciones de valdecoxib de disgregación intraoral preparadas mediante un procedimiento de desecación por pulverizacion
SE0202287D0 (sv) New compounds
DOP2003000655A (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
PE122099A1 (es) Budesonida sola o en combinacion con acido ursodesoxicolico en la terapia de enfermedades colestasicas del higado